Lilly weight loss drug shows potential best-in-class profile, says JPMorgan

JPMorgan analyst Chris Schott says Eli Lilly’s Phase 2 retatrutide data suggest a potential best-in-class weight loss profile for the drug. In the study, retatrutide showed a 24% weight loss in the 48-week treatment period and had not plateaued, suggesting potential peak weight loss in the upper 20%s, the analyst tells investors in a research note. The firm says the efficacy could have been higher if the study population had consisted of a higher proportion of women. JPMorgan sees Eli Lilly as positioned to address a full spectrum of type 2 diabetes and obesity patients with the overall incretin market largely remaining a duopoly. It keeps an Overweight rating on the shares.